ADGN-531 / Aanastra, Divincell - LARVOL DELTA

mRNA-Mediated Rescue Loss of p53 Tumor Suppressor Function as a Potent New Strategy for Cancer Therapy across Pan-p53 Alterations. (ASGCT 2025) - "ADGN-531/sotorasib synergy was evaluated in vitro on NCI-H358 (p53 null/KRAS G12C ) and Mia-PACA (p53 R48W /KRAS G12C ) cells and in vivo on NCI-H358 mouse xenograft. Our study provides a proof-of-concept that restoration of tumor suppressor function by ADGN-531 could be used as a single agent therapy in P53 altered tumors independent of other driver mutations e.g., KRAS, or with other therapies for potent combinatorial cancer treatment. Disease Focus of Abstract:Cancer Solid Tumors"

Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • BAX • CDKN1A • KRAS • TP53

Peptide Based Nanoparticle-Platform for Extrahepatic Delivery of Functional mRNAs (ASGCT 2024) - "ADGN nanoparticles constitute a safe and effective platform for tissue-specific delivery of functional mRNAs with potential clinical applications. Our study provides a proof-of-concept that restoration of tumor suppressor function by ADGN-531 or ADGN-903 could be used as a single agent therapy in P53 or BRCA-1 altered tumors independent of other driver mutations or with other therapies for potent combinatorial cancer treatment."

Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • BRCA • BRCA1

In vivo rescue of p53 tumor suppressor function with ADGN-531 across Pan-p53 alterations (AACR 2024) - "ADGN-531/sotorasib synergy was evaluated in vitro on NCI-H358 (p53 null/KRASG12C) and Mia-PACA (p53R48W/KRASG12C) cells and in vivo on NCI-H358 mouse xenograft. ADGN-531 treatments are well tolerated, no sign of clinical toxicity was detected after single or repeated administrations.ADGN-531 is effective in rescuing p53 function both in vitro and in vivo across a wide range of p53 alterations. Our study provides a proof-of-concept that restoration of tumor suppressor function by ADGN-531 could be used as a single agent therapy in P53 altered tumors independent of other driver mutations e.g., KRAS, or with other therapies for potent combinatorial cancer treatment."

Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • CDKN1A • KRAS • TP53

Aanastra Inc to Present Multiple Posters on RNA Therapeutics at the American Association for Cancer Research (AACR) Annual Meeting 2024 (GlobeNewswire) - "Aanastra, Inc...announced poster presentations at the 2024 American Association for Cancer Research (AACR), taking place April 5-10, 2024, in San Diego, CA."

Preclinical • Oncology • Solid Tumor